IDP Pharma, in collaboration with Carlos III Research Institute (ISCIII) and Hospital 12 de Octubre in Madrid, has published a study in the journal Neurotherapeutics (https://link.springer.com/article/10.1007/s13311-021-01176-6) which reveals that a new experimental drug, IDP-410, directly engages the key oncoprotein N-MYC and reduces the growth of glioblastomas in animal models. The Company expects to develop further IDP-410 to bring a novel therapy to patients which currently lack treatment options.
